SCHEMBL10162335

SCHEMBL10162335

CC(=O)c1ccc([C@H](C)NC(=O)c2cc(C(=O)NCc3ccc(F)c(F)c3)nc3ncnn23)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CACNA1G O43497 3/20 0.43
CACNA1H O95180 3/20 0.43
CACNA1I Q9P0X4 3/20 0.43
PDE2A O00408 1/20 0.41
MMP13 P45452 6/20 0.40
PTGER4 P35408 1/20 0.40
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
MMP10 P09238 1/20 0.37
MMP9 P14780 1/20 0.37
MMP8 P22894 1/20 0.37
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MET P08581 1/20 0.36
RAB9A P51151 1/20 0.36
S1PR3 Q99500 1/20 0.36
MAPT P10636 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10162340 0.94 MMP13 (0.48) CACNA1GCACNA1HCACNA1IPDE2AMMP13
SCHEMBL10162330 0.93 MMP13 (0.39) CACNA1GCACNA1HCACNA1IPDE2AMMP13
SCHEMBL10162458 0.90 MMP13 (0.44) CACNA1GCACNA1HCACNA1IMMP13PTGER4
SCHEMBL8253135 0.87 MMP13 (0.53) MMP13PTGER4MMP10MMP9MMP8
SCHEMBL10165591 0.86 MMP13 (0.51) CACNA1GCACNA1HCACNA1IPDE2AMMP13
SCHEMBL8256059 0.85 MMP13 (0.47) CACNA1GCACNA1HCACNA1IPDE2AMMP13
SCHEMBL10162443 0.83 MMP13 (0.55) PDE2AMMP13MMP10MMP9MMP8
SCHEMBL10162454 0.82 MMP13 (0.42) PDE2AMMP13PTGER4MMP10MMP9
SCHEMBL13161270 0.81 MMP8 (0.48) MMP13MAOAMMP8ALDH1A1
SCHEMBL8183920 0.80 MMP13 (0.52) CACNA1GCACNA1HCACNA1IPDE2AMMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 CACNA1G 2170/4885CACNA1H 2465/4885CACNA1I 1645/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 CACNA1G 2170/4885CACNA1H 2465/4885CACNA1I 1645/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 CACNA1G 2170/4885CACNA1H 2465/4885CACNA1I 1645/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 CACNA1G 2170/4885CACNA1H 2465/4885CACNA1I 1645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.